logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme Gets Complete Response Letter From FDA On Lemtrada Application

Genzyme, a Sanofi company (SNY,SNYNF.PK), said it has received a Complete Response Letter from the U.S. Food and Drug Administration or FDA for its supplemental Biologics License Application seeking approval of Lemtrada or alemtuzumab for the treatment of relapsing forms of multiple sclerosis. Alemtuzumab is a monoclonal antibody that selectively targets CD52, a protein abundant on T and B cells.

A Complete Response Letter informs companies that an application is not yet ready for approval. FDA has taken the position that Genzyme has not submitted evidence from adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects. Genzyme understands that the conclusion is related to the design of the completed Phase 3 active comparator studies of Lemtrada in relapsing-remitting MS patients. Moreover, FDA has taken the position that one or more additional active comparator trials of different design and execution are needed prior to the Lemtrada approval.

Genzyme strongly disagrees with the FDA's conclusions and intends to appeal the agency's decision.

Lemtrada is approved in the European Union, Canada, and Australia, and additional marketing applications for Lemtrada are under review by regulatory agencies worldwide. Sanofi does not expect that the CVR milestone of U.S. approval of Lemtrada by March 31, 2014 would be met.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Federal Aviation Administration said several pilots complained about pointing of strong green laser beams at planes flying over Long Island. The location was around Farmingdale, during 9.30 pm and 10 pm. Searches are on to locate the exact source of the laser beam. The Federal official suspects that the beam came from a hand-held device. Discount retailer Big Lots, Inc. Friday reported an increase in income from continuing operations for the first quarter, from last year. The company also registered a surge in net income particularly as it had carried a loss from discontinued operations last year. Taco Bell, a division of Yum! Brands Inc, is planning to test delivery of food items on college campuses, the Street reported. The move comes at a time the fast food chain seeks to leverage demand for its popular breakfast and dinner items.
comments powered by Disqus
RELATED NEWS
Trade SNY now with 
Follow RTT